Rossari Biotech Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 12, 2025, 11:24 am

Market Cap	3,888 Cr.
Current Price	702
High / Low	973/568
Stock P/E	28.5
Book Value	214
Dividend Yield	0.07 %
ROCE	15.8 %
ROE	12.2 %
Face Value	2.00
PEG Ratio	2.92

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Rossari Biotech Ltd

Competitors of Rossari Biotech Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
HP Adhesives Ltd	470 Cr.	51.2	108/42.6	26.4	20.0	0.59 %	13.9 %	10.1 %	2.00
Haryana Leather Chemicals Ltd	34.1 Cr.	69.4	124/62.6	14.8	87.4	1.44 %	8.04 %	5.47 %	10.0
Hardcastle & Waud Mfg Co Ltd	49.8 Cr.	732	1,178/600	38.6	670	0.00 %	6.20 %	2.87 %	10.0
Grauer & Weil (India) Ltd	4,793 Cr.	106	120/78.0	30.5	20.7	0.47 %	23.8 %	18.0 %	1.00
DMCC Speciality Chemicals Ltd	634 Cr.	254	453/241	29.4	91.1	0.39 %	14.6 %	9.87 %	10.0
Industry Average	13,367.12 Cr	822.05		52.14	179.17	0.41%	12.92%	25.24%	6.44

All Competitor Stocks of Rossari Biotech Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	439	435	425	389	406	411	483	464	473	490	498	513	580
Expenses	387	377	369	335	352	353	420	400	409	425	432	448	510
Operating Profit	52	58	57	54	55	58	64	64	64	65	66	65	69
OPM %	12%	13%	13%	14%	13%	14%	13%	14%	13%	13%	13%	13%	12%
Other Income	3	1	1	1	3	2	1	4	1	1	1	1	2
Interest	5	5	8	5	4	6	5	4	3	4	4	5	6
Depreciation	17	15	16	16	16	14	15	15	16	15	15	18	18
Profit before tax	34	39	34	35	37	39	45	48	46	47	48	42	48
Tax %	30%	26%	29%	26%	22%	26%	26%	28%	25%	26%	27%	25%	28%
Net Profit	24	29	24	26	29	29	33	34	34	35	35	32	34
EPS in Rs	4.37	5.21	4.34	4.66	5.25	5.30	5.97	6.23	6.18	6.32	6.39	5.73	6.22

Last Updated: May 31, 2025, 7:56 am

Below is a detailed analysis of the quarterly data for Rossari Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 580.00 Cr.. The value appears strong and on an upward trend. It has increased from 513.00 Cr. (Dec 2024) to 580.00 Cr., marking an increase of 67.00 Cr..
For Expenses, as of Mar 2025, the value is 510.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 448.00 Cr. (Dec 2024) to 510.00 Cr., marking an increase of 62.00 Cr..
For Operating Profit, as of Mar 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 65.00 Cr. (Dec 2024) to 69.00 Cr., marking an increase of 4.00 Cr..
For OPM %, as of Mar 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 13.00% (Dec 2024) to 12.00%, marking a decrease of 1.00%.
For Other Income, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Dec 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
For Interest, as of Mar 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Dec 2024) to 6.00 Cr., marking an increase of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 18.00 Cr..
For Profit before tax, as of Mar 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Dec 2024) to 48.00 Cr., marking an increase of 6.00 Cr..
For Tax %, as of Mar 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Dec 2024) to 28.00%, marking an increase of 3.00%.
For Net Profit, as of Mar 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Dec 2024) to 34.00 Cr., marking an increase of 2.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 6.22. The value appears strong and on an upward trend. It has increased from 5.73 (Dec 2024) to 6.22, marking an increase of 0.49.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:17 pm

Metric	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	516	600	709	1,483	1,656	1,831	2,080
Expenses	438	495	586	1,299	1,433	1,581	1,815
Operating Profit	78	105	124	184	223	250	265
OPM %	15%	17%	17%	12%	13%	14%	13%
Other Income	1	4	9	13	6	8	5
Interest	3	4	3	13	22	19	18
Depreciation	12	17	23	48	63	60	67
Profit before tax	63	88	107	136	144	178	185
Tax %	28%	26%	25%	28%	26%	26%	26%
Net Profit	46	65	80	98	107	131	136
EPS in Rs	103.82	12.86	15.45	17.74	19.45	23.66	24.63
Dividend Payout %	0%	4%	3%	3%	3%	2%	2%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	41.30%	23.08%	22.50%	9.18%	22.43%	3.82%
Change in YoY Net Profit Growth (%)	0.00%	-18.23%	-0.58%	-13.32%	13.25%	-18.61%

Rossari Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	28%
3 Years:	12%
TTM:	14%

Compounded Profit Growth
10 Years:	%
5 Years:	16%
3 Years:	12%
TTM:	5%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	-6%
1 Year:	-13%

Return on Equity
10 Years:	%
5 Years:	14%
3 Years:	13%
Last Year:	12%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:26 am

Month	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	4	10	10	11	11	11	11
Reserves	119	277	398	794	904	1,037	1,174
Borrowings	8	67	0	8	74	119	218
Other Liabilities	118	118	152	442	375	401	482
Total Liabilities	250	471	561	1,255	1,364	1,567	1,886
Fixed Assets	74	94	181	607	585	578	598
CWIP	3	22	0	1	16	47	140
Investments	0	18	0	36	51	63	84
Other Assets	173	338	379	611	712	880	1,063
Total Assets	250	471	561	1,255	1,364	1,567	1,886

Below is a detailed analysis of the balance sheet data for Rossari Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.00 Cr..
For Reserves, as of Mar 2025, the value is 1,174.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,037.00 Cr. (Mar 2024) to 1,174.00 Cr., marking an increase of 137.00 Cr..
For Borrowings, as of Mar 2025, the value is 218.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 119.00 Cr. (Mar 2024) to 218.00 Cr., marking an increase of 99.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 482.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 401.00 Cr. (Mar 2024) to 482.00 Cr., marking an increase of 81.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 1,886.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,567.00 Cr. (Mar 2024) to 1,886.00 Cr., marking an increase of 319.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 598.00 Cr.. The value appears strong and on an upward trend. It has increased from 578.00 Cr. (Mar 2024) to 598.00 Cr., marking an increase of 20.00 Cr..
For CWIP, as of Mar 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Mar 2024) to 140.00 Cr., marking an increase of 93.00 Cr..
For Investments, as of Mar 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Mar 2024) to 84.00 Cr., marking an increase of 21.00 Cr..
For Other Assets, as of Mar 2025, the value is 1,063.00 Cr.. The value appears strong and on an upward trend. It has increased from 880.00 Cr. (Mar 2024) to 1,063.00 Cr., marking an increase of 183.00 Cr..
For Total Assets, as of Mar 2025, the value is 1,886.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,567.00 Cr. (Mar 2024) to 1,886.00 Cr., marking an increase of 319.00 Cr..

Notably, the Reserves (1,174.00 Cr.) exceed the Borrowings (218.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	71	57	48	29	152	43	137
Cash from Investing Activity +	-37	-190	-37	-299	-181	-103	-183
Cash from Financing Activity +	-29	157	-25	292	61	16	65
Net Cash Flow	5	23	-14	22	32	-44	19

Free Cash Flow

Month	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	70.00	38.00	124.00	176.00	149.00	131.00	47.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	61	57	74	75	78	85
Inventory Days	59	57	75	63	59	80
Days Payable	114	95	104	61	56	62
Cash Conversion Cycle	6	19	46	76	80	103
Working Capital Days	25	39	60	64	57	85
ROCE %		38%	29%	24%	18%	18%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	68.56%	68.56%	68.56%	68.56%	68.46%	68.44%	68.44%	68.44%	68.35%	68.34%	68.32%	68.32%
FIIs	8.46%	9.13%	9.03%	8.51%	8.84%	8.63%	7.46%	6.12%	5.74%	4.14%	4.02%	3.83%
DIIs	12.87%	12.77%	12.29%	13.02%	14.15%	14.08%	15.09%	17.71%	17.68%	18.06%	17.74%	16.87%
Public	10.10%	9.54%	10.12%	9.91%	8.55%	8.85%	9.01%	7.73%	8.23%	9.45%	9.90%	10.98%
No. of Shareholders	65,831	76,494	92,099	98,565	95,664	97,081	96,634	95,371	95,200	1,00,423	98,859	1,00,475

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
SBI Small Cap Fund	2,016,798	0.64	145.68	2,016,798	2025-04-22 14:12:24	0%
UTI Flexi Cap Fund	1,915,752	0.54	138.38	1,915,752	2025-04-22 15:56:53	0%
SBI Flexi Cap Fund	1,648,008	0.64	119.04	1,648,008	2025-04-22 15:56:53	0%
Canara Robeco Small Cap Fund	1,067,293	0.93	85.29	1,067,293	2025-04-22 15:56:53	0%
UTI Small Cap Fund	407,215	0.85	29.42	407,215	2025-04-22 15:56:53	0%
Bandhan Focused Equity Fund	228,933	1.23	18.3	228,933	2025-04-22 15:56:53	0%
UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan	143,597	0.2	10.37	143,597	2025-04-22 15:56:53	0%
UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan	143,597	0.2	10.37	143,597	2025-04-22 15:56:53	0%
Nippon India Nifty Smallcap 250 Index Fund	12,015	0.1	0.96	12,015	2025-04-22 15:56:54	0%
SBI Tax Advantage Fund - Series III	7,000	1.55	0.51	7,000	2025-04-22 15:56:54	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	24.66	23.67	19.46	17.81	15.56
Diluted EPS (Rs.)	24.63	23.62	19.38	17.70	15.47
Cash EPS (Rs.)	36.57	34.56	30.68	26.19	19.73
Book Value[Excl.RevalReserv]/Share (Rs.)	214.12	189.65	165.93	146.25	78.72
Book Value[Incl.RevalReserv]/Share (Rs.)	214.12	189.65	165.93	146.25	78.72
Revenue From Operations / Share (Rs.)	375.74	331.35	300.22	269.36	136.60
PBDIT / Share (Rs.)	48.60	46.56	41.43	35.50	25.47
PBIT / Share (Rs.)	36.49	35.63	30.02	26.77	21.07
PBT / Share (Rs.)	33.27	32.12	25.97	24.47	20.49
Net Profit / Share (Rs.)	24.46	23.62	19.27	17.46	15.34
NP After MI And SOA / Share (Rs.)	24.63	23.66	19.45	17.74	15.45
PBDIT Margin (%)	12.93	14.05	13.79	13.17	18.64
PBIT Margin (%)	9.71	10.75	9.99	9.93	15.42
PBT Margin (%)	8.85	9.69	8.65	9.08	15.00
Net Profit Margin (%)	6.50	7.12	6.41	6.48	11.22
NP After MI And SOA Margin (%)	6.55	7.13	6.47	6.58	11.30
Return on Networth / Equity (%)	11.50	12.47	11.71	12.13	19.62
Return on Capital Employeed (%)	14.85	17.15	16.22	15.31	26.61
Return On Assets (%)	7.19	8.31	7.84	7.77	14.29
Long Term Debt / Equity (X)	0.08	0.03	0.03	0.00	0.00
Total Debt / Equity (X)	0.15	0.10	0.08	0.01	0.00
Asset Turnover Ratio (%)	1.20	1.25	1.26	1.63	1.37
Current Ratio (X)	1.94	1.99	2.08	2.07	2.36
Quick Ratio (X)	1.28	1.32	1.54	1.42	1.73
Inventory Turnover Ratio (X)	4.08	5.22	5.70	6.80	5.66
Dividend Payout Ratio (NP) (%)	2.02	2.11	2.56	2.81	3.16
Dividend Payout Ratio (CP) (%)	1.35	1.44	1.61	1.88	2.46
Earning Retention Ratio (%)	97.98	97.89	97.44	97.19	96.84
Cash Earning Retention Ratio (%)	98.65	98.56	98.39	98.12	97.54
Interest Coverage Ratio (X)	15.11	13.28	10.24	15.44	44.20
Interest Coverage Ratio (Post Tax) (X)	8.60	7.74	5.76	8.60	27.62
Enterprise Value (Cr.)	3475.13	3801.34	3233.01	4985.62	5300.00
EV / Net Operating Revenue (X)	1.67	2.08	1.95	3.36	7.47
EV / EBITDA (X)	12.91	14.78	14.15	25.51	40.08
MarketCap / Net Operating Revenue (X)	1.61	2.04	1.98	3.39	7.60
Retention Ratios (%)	97.97	97.88	97.43	97.18	96.83
Price / BV (X)	2.82	3.56	3.59	6.25	13.18
Price / Net Operating Revenue (X)	1.61	2.04	1.98	3.39	7.60
EarningsYield	0.04	0.03	0.03	0.01	0.01

After reviewing the key financial ratios for Rossari Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.67 (Mar 24) to 24.66, marking an increase of 0.99.
For Diluted EPS (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.63, marking an increase of 1.01.
For Cash EPS (Rs.), as of Mar 25, the value is 36.57. This value is within the healthy range. It has increased from 34.56 (Mar 24) to 36.57, marking an increase of 2.01.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 375.74. It has increased from 331.35 (Mar 24) to 375.74, marking an increase of 44.39.
For PBDIT / Share (Rs.), as of Mar 25, the value is 48.60. This value is within the healthy range. It has increased from 46.56 (Mar 24) to 48.60, marking an increase of 2.04.
For PBIT / Share (Rs.), as of Mar 25, the value is 36.49. This value is within the healthy range. It has increased from 35.63 (Mar 24) to 36.49, marking an increase of 0.86.
For PBT / Share (Rs.), as of Mar 25, the value is 33.27. This value is within the healthy range. It has increased from 32.12 (Mar 24) to 33.27, marking an increase of 1.15.
For Net Profit / Share (Rs.), as of Mar 25, the value is 24.46. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.46, marking an increase of 0.84.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.66 (Mar 24) to 24.63, marking an increase of 0.97.
For PBDIT Margin (%), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 14.05 (Mar 24) to 12.93, marking a decrease of 1.12.
For PBIT Margin (%), as of Mar 25, the value is 9.71. This value is below the healthy minimum of 10. It has decreased from 10.75 (Mar 24) to 9.71, marking a decrease of 1.04.
For PBT Margin (%), as of Mar 25, the value is 8.85. This value is below the healthy minimum of 10. It has decreased from 9.69 (Mar 24) to 8.85, marking a decrease of 0.84.
For Net Profit Margin (%), as of Mar 25, the value is 6.50. This value is within the healthy range. It has decreased from 7.12 (Mar 24) to 6.50, marking a decrease of 0.62.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.55. This value is below the healthy minimum of 8. It has decreased from 7.13 (Mar 24) to 6.55, marking a decrease of 0.58.
For Return on Networth / Equity (%), as of Mar 25, the value is 11.50. This value is below the healthy minimum of 15. It has decreased from 12.47 (Mar 24) to 11.50, marking a decrease of 0.97.
For Return on Capital Employeed (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has decreased from 17.15 (Mar 24) to 14.85, marking a decrease of 2.30.
For Return On Assets (%), as of Mar 25, the value is 7.19. This value is within the healthy range. It has decreased from 8.31 (Mar 24) to 7.19, marking a decrease of 1.12.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.15, marking an increase of 0.05.
For Asset Turnover Ratio (%), as of Mar 25, the value is 1.20. It has decreased from 1.25 (Mar 24) to 1.20, marking a decrease of 0.05.
For Current Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.94, marking a decrease of 0.05.
For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.28, marking a decrease of 0.04.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.08. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 4.08, marking a decrease of 1.14.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 20. It has decreased from 2.11 (Mar 24) to 2.02, marking a decrease of 0.09.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 20. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
For Earning Retention Ratio (%), as of Mar 25, the value is 97.98. This value exceeds the healthy maximum of 70. It has increased from 97.89 (Mar 24) to 97.98, marking an increase of 0.09.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.65. This value exceeds the healthy maximum of 70. It has increased from 98.56 (Mar 24) to 98.65, marking an increase of 0.09.
For Interest Coverage Ratio (X), as of Mar 25, the value is 15.11. This value is within the healthy range. It has increased from 13.28 (Mar 24) to 15.11, marking an increase of 1.83.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 8.60, marking an increase of 0.86.
For Enterprise Value (Cr.), as of Mar 25, the value is 3,475.13. It has decreased from 3,801.34 (Mar 24) to 3,475.13, marking a decrease of 326.21.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.67, marking a decrease of 0.41.
For EV / EBITDA (X), as of Mar 25, the value is 12.91. This value is within the healthy range. It has decreased from 14.78 (Mar 24) to 12.91, marking a decrease of 1.87.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
For Retention Ratios (%), as of Mar 25, the value is 97.97. This value exceeds the healthy maximum of 70. It has increased from 97.88 (Mar 24) to 97.97, marking an increase of 0.09.
For Price / BV (X), as of Mar 25, the value is 2.82. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.82, marking a decrease of 0.74.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Rossari Biotech Ltd as of July 12, 2025 is: 595.68

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 12, 2025, Rossari Biotech Ltd is Overvalued by 15.15% compared to the current share price 702.00

Intrinsic Value of Rossari Biotech Ltd as of July 12, 2025 is: 653.91

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 12, 2025, Rossari Biotech Ltd is Overvalued by 6.85% compared to the current share price 702.00

Last 5 Year EPS CAGR: 9.78%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 21.17%, which is a positive sign. The company has higher reserves (671.86 cr) compared to borrowings (70.57 cr), indicating strong financial stability. The company has shown consistent growth in sales (261.43 cr) and profit (128.71 cr) over the years.	The stock has a high average Working Capital Days of 55.00, which may not be favorable. The stock has a high average Cash Conversion Cycle of 55.00, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Rossari Biotech Ltd:
1. Net Profit Margin: 6.5%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 14.85% (Industry Average ROCE: 12.92%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 11.5% (Industry Average ROE: 25.24%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 8.6
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.28
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 28.5 (Industry average Stock P/E: 52.14)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.15
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Rossari Biotech Ltd. is a Public Limited Listed company incorporated on 10/08/2009 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24100MH2009PLC194818 and registration number is 194818. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 1431.63 Cr. and Equity Capital is Rs. 11.07 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Chemicals - Speciality - Others	Rossari House, Golden Oak, LBS Marg, Surya Nagar, Mumbai Maharashtra 400079	investors@rossari.com http://www.rossari.com

Management
Name	Position Held
Mr. Edward Menezes	Executive Chairman
Mr. Sunil Chari	Managing Director
Mr. Aseem Dhru	Independent Director
Ms. Aparna Sharma	Independent Director
Ms. Esha Achan	Independent Director
Mr. Gurudas Aras	Independent Director

FAQ

What is the intrinsic value of Rossari Biotech Ltd?

Rossari Biotech Ltd's intrinsic value (as of 12 July 2025) is 595.68 15.15% lower the current market price of 702.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,888 Cr. market cap, FY2025-2026 high/low of 973/568, reserves of 1,174 Cr, and liabilities of 1,886 Cr.

What is the Market Cap of Rossari Biotech Ltd?

The Market Cap of Rossari Biotech Ltd is 3,888 Cr..

What is the current Stock Price of Rossari Biotech Ltd as on 12 July 2025?

The current stock price of Rossari Biotech Ltd as on 12 July 2025 is 702.

What is the High / Low of Rossari Biotech Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Rossari Biotech Ltd stocks is ₹973/568.

What is the Stock P/E of Rossari Biotech Ltd?

The Stock P/E of Rossari Biotech Ltd is 28.5.

What is the Book Value of Rossari Biotech Ltd?

The Book Value of Rossari Biotech Ltd is 214.

What is the Dividend Yield of Rossari Biotech Ltd?

The Dividend Yield of Rossari Biotech Ltd is 0.07 %.

What is the ROCE of Rossari Biotech Ltd?

The ROCE of Rossari Biotech Ltd is 15.8 %.

What is the ROE of Rossari Biotech Ltd?

The ROE of Rossari Biotech Ltd is 12.2 %.

What is the Face Value of Rossari Biotech Ltd?

The Face Value of Rossari Biotech Ltd is 2.00.